Drug maker Aurobindo Pharma Ltd on Saturday (December 21) said its step-down subsidiary CuraTeQ Biologics s.r.o. has received marketing authorisation from the UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Bevqolva, its biosimilar version of bevacizumab.
“…CuraTeQ Biologics s.r.o., a step-down subsidiary of the Company has obtained marketing authorisation from UK’s Medicines and Healthcare products Regulatory Agency (MHRA) for Bevqolva, its bevacizumab biosimilar version,” Aurobindo Pharma said in a regulatory filing.
Bevqolva 25 mg/mL concentrate for infusion will be available in 4 mL (100 mg) and 16 mL (400 mg) single-use vials for infusion into veins.
Bevacizumab is used in the treatment of multiple cancers including metastatic colorectal cancer, recurrent or metastatic non-squamous non-small cell lung cancer, advanced and/or metastatic renal cell carcinoma, cervical cancer and epithelial ovarian, fallopian tube and primary peritoneal cancer.
Article excerpt reposted from CNBCTV18.
